Form 8-K

8-K — Vivos Therapeutics, Inc.

Accession: 0001493152-26-039736

Filed: 2026-08-21

Period: 2026-08-20

CIK: 0001716166

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001716166

2026-08-20

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 20, 2026

Vivos

Therapeutics, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-39796

81-3224056

(State

or other jurisdiction

(Commission

(I.R.S.

Employer

incorporation)

File

Number)

Identification

No.)

7921

Southpark Plaza, Suite 210

Littleton,

Colorado 80120

(Address

of principal executive offices) (Zip Code)

(866)

908-4867

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.0001 per share

VVOS

The

NASDAQ Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01. Regulation FD Disclosure.

August 20, 2026, Vivos Therapeutics, Inc. issued a press release announcing the opening of a new testing and treatment facility.

copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The

information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section,

and shall not be deemed incorporated by reference into any filing under the Securities Act, or the Exchange Act, as amended, except as

expressly set forth by specific reference in such filing.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated August 20, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

VIVOS

THERAPEUTICS, INC.

Dated: August 21, 2026 By: /s/

R. Kirk Huntsman

Name: R.

Kirk Huntsman

Title: Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Vivos

Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing

and Treatment

New

Location Expected to More Than Double Annual Revenue Production Capacity to Over $10 Million

Official

Grand Opening Slated for August 27 in Henderson, Nevada With Prominent Industry Opinion Leaders, Sleep Physicians, Dentists Among Scheduled

Attendees

LITTLETON,

Colo., August 20, 2026 – Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading

medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities

for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, today announced the official Grand

Opening of its latest state-of-the-art diagnostic, testing, and treatment location in Henderson, Nevada. The Company expects this new

full-service center will more than double the annual production capacity in Henderson to more than $10 million. At full capacity, the

facility is expected to employ up to 30 personnel, including board certified medical doctors, specially trained dentists, nurse practitioners,

and a full complement of clinical and support personnel as part of the Company’s Sleep Centers of Nevada network.

Sleep

Centers of Nevada Founder and Chief Medical Officer, R. D. Prabhu, M.D. said, “Our new Henderson facility is a state-of-the-art

center that brings together two highly specialized teams to deliver the most comprehensive sleep-medicine care in Nevada. For the first

time, patients can receive diagnostic testing, clinical evaluation, and advanced treatment — including FDA-cleared oral appliance

therapy, airway-focused dental sleep medicine, laser therapy, and myofunctional therapy — all in one location.”

continued, “We believe there is no other integrated sleep and airway center like this in the United States. With more than 200,000

Nevadans living with undiagnosed sleep apnea, this facility will make a meaningful difference in the health of our community.”

Vivos’

Chief Executive Officer, Kirk Huntsman, added, “This added production capacity will go a long way to help us keep up with the growing

level of referrals coming into our centers each month. Just since the May-June timeframe, we’ve seen total incoming referrals more

than double across the Las Vegas market, so this added production capacity comes at a very good time, and should have an immediate impact

on revenue in that market. This new center in Henderson represents our most refined platform model where we are able to provide patients

with extensive testing services as well as a full spectrum of treatment options to ensure that patients who accept treatment receive

a customized plan to get started almost immediately.”

About

Vivos Therapeutics, Inc.

Vivos

Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative

diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities

such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration

(FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’

groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating

severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children.

OSA

and insomnia affect an estimated 1 Billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their

condition. These chronic disorders are not just a sleep issue—they are closely linked to many serious chronic health conditions.

While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not

fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos

CARE oral medical devices are designed to help address anatomical factors are often associated with OSA.

Through

innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering

healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos

calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective

solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For

more information, visit www.vivos.com.

Cautionary

Note Regarding Forward-Looking Statements

This

press release, including statements of the Company’s management and other parties made in connection therewith, contains “forward-looking

statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act

of 1934, as amended) concerning future events. Words such as “may,” “would,” “should,” “expects,”

“projects,” “potential,” “intends,” “plans,” “believes,” “anticipates,”

“hopes,” “estimates,” “goal,” “aim,” and variations of such words and similar expressions

are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, statements

regarding: the expected timing and benefits of the grand opening of the Company’s new Henderson, Nevada facility; the expectation

that the new facility will more than double annual production capacity to more than $10 million; anticipated staffing levels at the new

facility; recent patient referral trends and their anticipated impact on the Company’s revenue in the Las Vegas market; and the

potential impact of the foregoing on the Company’s competitive position, revenues, and overall growth.

These

statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject

to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and

adversely from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited

to: (i) the risk that the new facility will not be able to provide the anticipated financial and other benefits; (ii) the risk that the

anticipated production capacity increases will not materialize as anticipated; (iii) the risk that new or competing technology may limit

or extinguish the new location’s economic value to the Company; (iv) risks associated with regulatory scrutiny of, and adverse

publicity in, the sleep apnea and sleep disorder diagnosis and treatment sector; (v) the risk that Vivos may be unable to secure additional

financing to continue operations, acquire or affiliate with additional sleep center practices, or maintain its Nasdaq listing, when needed,

if at all; (vi) market and other conditions that could impact Vivos’ business or ability to obtain financing; (vii) the risk that

recent increases in patient referrals may not continue or may not translate into increased revenue, or that the Company may be unable

to recruit and retain the qualified medical, dental and clinical personnel needed to staff and operate the new facility; and (viii) other

risk factors described in Vivos’ filings with the Securities and Exchange Commission (the “SEC”), which are available

free of charge on the SEC’s website at www.sec.gov.

Except

to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to

any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change

in events, conditions, or circumstances on which any such statement is based.

Vivos

Investor Relations Contact:

Jennifer

Hauser, Executive Assistant to the CEO

jhauser@vivoslife.com

720-927-3125

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 20, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 20, 2026

Entity File Number

001-39796

Entity Registrant Name

Vivos

Therapeutics, Inc.

Entity Central Index Key

0001716166

Entity Tax Identification Number

81-3224056

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7921

Southpark Plaza

Entity Address, Address Line Two

Suite 210

Entity Address, City or Town

Littleton

Entity Address, State or Province

Entity Address, Postal Zip Code

80120

City Area Code

(866)

Local Phone Number

908-4867

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

VVOS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration